Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 17/20 | 0.84 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750178 | 0.92 | CASR (1.00) | CASRGFERMEN1KMT2A | |
| SCHEMBL5747231 | 0.91 | CASR (0.88) | CASRGFERALDH1A1MEN1KMT2A | |
| SCHEMBL5747388 | 0.90 | CASR (0.86) | CASRGFERSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5748183 | 0.89 | CASR (0.86) | CASR | |
| SCHEMBL5751262 | 0.89 | CASR (0.84) | CASRGFER | |
| SCHEMBL5751290 | 0.88 | CASR (1.00) | CASR | |
| SCHEMBL5749503 | 0.88 | CASR (0.77) | CASRGFER | |
| SCHEMBL5749558 | 0.88 | CASR (1.00) | CASR | |
| SCHEMBL5751312 | 0.86 | CASR (0.79) | CASRGFERMEN1KMT2A | |
| SCHEMBL5779646 | 0.85 | CASR (0.73) | CASRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558260-A4 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | NPS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| CN-1708306-A | Quinazolinone compounds as calcilytics | NPS PHARMA INC (US) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558260-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041755-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | CALCR, CALCRL, CASR | CASR 3/4885GFER 3259/4885ALDH1A1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.